Results 1 to 10 of about 34,901 (267)

Effect of β-Lactamase inhibitors on in vitro activity of β-Lactam antibiotics against Burkholderia cepacia complex species [PDF]

Antimicrobial Resistance and Infection Control, 2016
Background Bacteria belonging to the Burkholderia cepacia complex (Bcc) are an important cause of chronic respiratory tract infections in cystic fibrosis patients.
Annelien Everaert, Tom Coenye
doaj   +4 more sources

New β-Lactam/β-Lactamase Inhibitor Combination Antibiotics [PDF]

Pathogens
The growing problem of infections due to pathogens with antimicrobial resistance, especially Gram-negative bacteria, has led to the development of new β-lactam/β-lactamase inhibitor combination antibiotics.
Maria Sargianou, Panagiotis Stathopoulos, Christos Vrysis, Iva D. Tzvetanova, Matthew E. Falagas   +4 more
doaj   +2 more sources

Revisiting the Checkerboard to Inform Development of β-Lactam/β-Lactamase Inhibitor Combinations [PDF]

Antibiotics
A two-dimensional “checkerboard” array employing systematic titration (e.g., serial two-fold dilutions) is a well-established in vitro method for exploring the antibacterial effects of novel drug combinations.
Darren J. Bentley
doaj   +2 more sources

β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development [PDF]

Pathogens
Antimicrobial resistance remains a public health problem of global concern with a great health and financial burden. Its recognition as a threat by political leadership has boosted the research and development of new antibiotics and particularly novel ...
Angeliki Katsarou, Panagiotis Stathopoulos, Iva D. Tzvetanova, Christina-Maria Asimotou, Matthew E. Falagas   +4 more
doaj   +2 more sources

In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinations [PDF]

Microbiology Spectrum
Carbapenem-resistant Enterobacterales represent a major health threat and have few approved therapeutic options. Enterobacterales isolates were collected from hospitalized inpatients from 49 sites in six European countries (1 January–31 December 2020 ...
Anne Santerre Henriksen, Fabio Arena, Marie Attwood, Rafael Canton, Sören Gatermann, Thierry Naas, Ian Morrissey, Christopher Longshaw   +7 more
doaj   +2 more sources

The Triple Combination of Meropenem, Avibactam, and a Metallo-β-Lactamase Inhibitor Optimizes Antibacterial Coverage Against Different β-Lactamase Producers [PDF]

Engineering
This work explores the potential of a triple combination of meropenem (MEM), a novel metallo-β-lactamase (MBL) inhibitor (indole-2-carboxylate 58 (InC58)), and a serine-β-lactamase (SBL) inhibitor (avibactam (AVI)) for broad-spectrum activity against ...
Zhuoren Ling, Alistair James Macdonald Farley, Aditya Lankapalli, Yanfang Zhang, Shonnette Premchand-Branker, Kate Cook, Andrei Baran, Charlotte Gray-Hammerton, Claudia Orbegozo Rubio, Edgars Suna, Jordan Mathias, Jürgen Brem, Kirsty Sands, Maria Nieto-Rosado, Maria Mykolaivna Trush, Nadira Naznin Rakhi, Willames Martins, Yuqing Zhou, Christopher Joseph Schofield, Timothy Walsh   +19 more
doaj   +2 more sources

Dynamically chiral phosphonic acid-type metallo-β-lactamase inhibitors

Communications Chemistry
Antibiotic resistance is a growing global health threat that risks the lives of millions. Among the resistance mechanisms, that mediated by metallo-β-lactamases is of particular concern as these bacterial enzymes dismantle most β-lactam antibiotics ...
Kinga Virág Gulyás, Liping Zhou, Daniel Salamonsen, Andreas Prester, Kim Bartels, Robert Bosman, Paul Haffke, Jintian Li, Viola Tamási, Fritz Deufel, Johannes Thoma, Anna Andersson Rasmussen, Miklós Csala, Hanna-Kirsti Schroder Leiros, Zhijian Xu, Mikael Widersten, Holger Rohde, Eike C. Schulz, Weiliang Zhu, Máté Erdélyi   +19 more
doaj   +6 more sources

Characterization of GQA as a novel β-lactamase inhibitor of CTX-M-15 and KPC-2 enzymes [PDF]

Microbial Cell Factories
β-lactam resistance is a significant global public health issue. Outbreaks of bacteria resistant to extended-spectrum β-lactams and carbapenems are serious health concerns that not only complicate medical care but also impact patient outcomes.
Lamiaa A. Al-Madboly, Mohamed A. Abd El-Salam, Jairo K. Bastos, Shaimaa Aboukhatwa, Rasha M. El-Morsi   +4 more
doaj   +2 more sources

In vitro effects of the new oral β-lactamase inhibitor xeruborbactam in combination with oral β-lactams against clinical Mycobacterium abscessus isolates [PDF]

Microbiology Spectrum
Non-tuberculosis mycobacteria (NTM), particularly Mycobacterium abscessus subsp. abscessus (M. abscessus), are increasingly being recognized as etiological agents of NTM pulmonary disease. However, treatment options for M.
Izumi Yamatani, Akio Aono, Keiji Fujiwara, Takahiro Asami, Keisuke Kamada, Yuta Morishige, Yuriko Igarashi, Kinuyo Chikamatsu, Yoshiro Murase, Hiroyuki Yamada, Akiko Takaki, Kosaku Komiya, Satoshi Mitarai   +12 more
doaj   +2 more sources

Molecular Docking Approach of Viscosin as Antibacterial for Methicillin-resistant Staphylococcus Aureus Via β-Lactamase Inhibitor Mechanism

Clinical and Research Journal in Internal Medicine, 2021
Background: β-lactamase is an enzyme that plays a role in the occurrence of antibiotic resistance against Methicillin-resistant Staphylococcus aureus (MRSA) bacteria. Viscosin is a lipopeptide biosurfactant produced by the Pseudomonas group bacteria.
Mokhamad Fahmi Rizki Syaban, Nabila Erina Erwan, Muhammad Rafif Raihan Syamsuddin, Fatimah Az Zahra, Faradilah Lukmana Sabila   +4 more
openaire   +1 more source